Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
2023年2月23日 - 10:45PM
Jeffs' Brands Ltd (the “Company” or “Jeffs’ Brands”) (Nasdaq:
JFBR), a data-driven e-commerce company operating on the Amazon
Marketplace, today announced that it has entered into a definitive
agreement (the “Agreement”) with SciSparc Ltd. (“SciSparc”)
(Nasdaq: SPRC), to purchase from it approximately 49% of the
outstanding capital stock of SciSparc Nutraceuticals Inc. (the
“Subsidiary”), a wholly-owned subsidiary of SciSparc that owns
WellutionTM, a top-selling Amazon.com Marketplace food supplements
and cosmetics brand (the “Brand”), for $2.5 million in cash. The
stock interest of Jeffs’ Brands in the Subsidiary is expected to be
held by a wholly-owned Delaware subsidiary of Jeffs’ Brands. In
addition, the Agreement also includes a mutual share exchange
between SciSparc and the Company of restricted shares (the
“Share”), in the total amount of $300,000. The number of
shares in the share exchange will be calculated based on the
average closing price of the relevant company’s shares for 30
consecutive trading days ending on the third trading day
immediately prior to closing the transaction. The closing of the
transaction is subject to certain customary conditions and is
expected to be completed within seven business days. At closing,
the Company and the Subsidiary will enter into a consulting
agreement by which the Company will provide management services for
the Brand for a monthly fee of $20,000. The agreement is for an
undefined period of time, and may be terminated by either party
with 30-days’ advance notice.
The Brand is profitable with millions of dollars
in gross annual sales on the Amazon market place.
The Brand sells dozens of hemp-based, top-ranked
products, including hemp gummies, hemp oil capsules, hemp gel, hemp
cream, detox pills, height pills, antibacterial creams, and
anti-aging creams, among other beauty and hair treatment products
that are all manufactured in the United States.
The Brand offers eight variations of natural
hemp candy supplements under two parent Amazon Standard
Identification Number (each, an “ASIN”) on Amazon that are
differentiated by their hemp oil potency. The leading parent ASIN,
that was launched in 2019, has received over 26,500 reviews and has
consistently ranked as the #1 best seller in the category. In
total, the Brand had approximately 40,000 product reviews to date,
most of which are 4 and 5-star reviews.
Mr. Oz Adler, the Chairman and a director of the
Company is the Chief Executive Officer and Chief Financial Officer
of SciSparc, Mr. Amitai Weiss, the Chairman of SciSparc, is a
director of Jeff’s Brands, and Mr. Moshe Revach is a member of the
board of directors of the Company and SciSparc.
The Shares have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"), or any
states' securities laws and may not be offered or sold in the
United States, except pursuant to an effective registration
statement or an applicable exemption from the registration
requirements of the Securities Act.
About Jeffs’ Brands Ltd
Jeffs' Brands is transforming the world of
e-commerce by creating and acquiring products and turning them into
market leaders, tapping into vast, unrealized growth potential.
Through our stellar team’s insight into the FBA Amazon business
model, we’re using both human capability and advanced technology to
take products to the next level. For more information on Jeffs’
Brands Ltd visit https://jeffsbrands.com.
About SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. SciSparc’s focus is on creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the
treatment of Tourette Syndrome, for the treatment of Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and status
epilepticus.
Forward-Looking Statement
Disclaimer
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities
Act, and Section 21E of the Securities Exchange Act of 1934, as
amended, that are intended to be covered by the “safe harbor”
created by those sections. Forward-looking statements, which are
based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of forward-looking terms such as “believe,” “expect,” “may,”
“should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,”
“anticipate” or other comparable terms. For example, we are using
forward-looking statements when we are discussing the Company’s
expectations regarding the closing of the transaction and the
satisfaction of customary closing conditions related to the
transaction. Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based
only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: our ability to adapt to
significant future alterations in Amazon’s policies; our ability to
sell our existing products and grow our brands and product
offerings, including by acquiring new brands; our ability to meet
our expectations regarding the revenue growth and the demand for
e-commerce; the overall global economic environment; the impact of
competition and new e-commerce technologies; general market,
political and economic conditions in the countries in which we
operate; projected capital expenditures and liquidity; the impact
of possible changes in Amazon’s policies and terms of use; and the
other risks and uncertainties described in the Registration
Statement on Form F-1, as amended, filed with the SEC related to
our initial public offering and our other filings with the SEC. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contact:
Michal EfratyAdi and Michal PR- IRInvestor
Relations, Israel+972-(0)52-3044404michal@efraty.com
Jeffs Brands (NASDAQ:JFBR)
過去 株価チャート
から 2 2025 まで 3 2025
Jeffs Brands (NASDAQ:JFBR)
過去 株価チャート
から 3 2024 まで 3 2025